Antigen-immunostimulatory oligonucleotide conjugates: Mechanisms and applications

Immunological Reviews

Volumn 199, Issue , 2004, Pages 217-226

  Datta, Sandip K ^a   Cho, Hearn J ^b   Takabayashi, Kenji ^a   Horner, Anthony A ^a   Raz, Eyal ^a  

^a University of California San Diego School of Medicine   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN; LINK PROTEIN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE;

ALLERGENICITY; ALLERGIC DISEASE; ANTIBODY RESPONSE; CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONJUGATE; CONJUGATION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; INFECTION PREVENTION; LINKAGE ANALYSIS; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MUCOSAL IMMUNITY; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMMUNICABLE DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNIZATION; NEOPLASMS; OLIGONUCLEOTIDES; TH1 CELLS;

EID: 2942515020     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00149.x     Document Type: Review

References (47)

1. Tokunaga T, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984;72:955-962.
2. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988;79:866-873.
3. Krieg AM, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
4. Bird AP. Functions for DNA methylation in vertebrates. Cold Spring Harb Symp Quant Biol 1993;58:281-285.
5. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol 1992;148:4072-4076.
6. Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen MD, Kornbluth RS, Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunosumulatory DNA sequences. Int Immunol 1999;11:1111-1118.
7. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996;93:2879-2883.
8. Roman M, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997;3:849-854.
9. Kobayashi H, et al. Immunostimulatory DNA pre-priming: a novel approach for prolonged Th1-biased immunity. Cell Immunol 1999;198:69-75.
10. + T cell dependent. J Immunol 1999;163:1880-1887.
11. Cho HJ, et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000;18:509-514.
12. Horner AA, et al. Immunostimulatory dna-based vaccines elicit multifaceted immune responses against hiv at systemic and mucosal sites. J Immunol 2001;167:1584-1591.
13. Datta SK, et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003;170:4102-4110.
14. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
15. Verthelyi D, Klinman DM. CpG ODN - Safety Considerations. In: Raz E, ed. Microbial DNA and Host Immunity. Totowa, New Jersey: Humana Press Inc., 2002:385-396.
16. Tighe H, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000;106:124-134.
17. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol 2000;164:5575-5582.
18. Takabayashi K, Tighe H, Beck L, Spiegelberg HL. Protein-immunostimulatory DNA-conjugate: a novel immmuogen. In: Raz E, ed. Microbial DNA and Host Immunity. Totowa, New Jersey: Humana Press Inc., 2002:175-188.
19. Tighe H, et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000;30:1939-1947.
20. Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999;17:19-25.
21. Shirota H, Sano K, Hirasawa N, Hattori T, Shirato K, Tamura G. Nover roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 2001;167:66-74.
22. Maurer T, et al. CpG-DNA aided cross-pressentation of soluble antigens by dendritic cells. Eur J Immunol 2002;32:2356-2364.
23. Heit A, et al. Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol 2003;170:2802-2805.
24. Starnes CO. Coley's toxins in perspective. Nature 1992;357:11-12.
25. Nauts HC, McLaren JR. Coley toxins - the first century. Adv Exp Med Biol 1990;267:483-500.
26. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-969.
27. Banchereau J, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
28. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001;94:459-473.
29. + T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol 2002;168:4907-4913.
30. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
31. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
32. + T-helper and a T-killer cell. Nature 1998;393:474-478.
33. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-258.
34. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
35. Hsu FJ, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997;89:3129-3135.
36. Kwak LW. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-1215.
37. Knuth A, Wolfel T, Klehmann E, Boon T, Meyerzum Buschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989;86:2804-2808.
38. McCluskie MJ, Weeranta R, Davis HL. Comparison of CpG DNA with other adjuvants for vaccination against hepatits B. In: Raz E, ed. Microbial DNA and Host Immunity. Totowa, New Jersey: Humana Press Inc., 2002:229-238.
39. Guidotu LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996;8:478-483.
40. van den Broek MF, Müller U, Huang S, Zinkernagel RM, Aguet M. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 1995;148:5-18.
41. + T cells. Science 1995;270:1811-1815.
42. Horner AA, et al. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J Allergy Clin Immunol 2002;110:413-420.
43. Horner AA, Nguyen MD, Ronaghy A, Cinman N, Verbeek S, Raz E. DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice. J Allergy Clin Immunol 2000;106:349-356.
44. Takabayashi K, Libet L, Chisolm D, Zubeldia J, Horner AA. Intranasal immunotherapy is more effective than intradermal immunotherapy for the induction of airway allergen tolerance in Th2-sensitized mice. J Immunol 2003;170:3898-3905.
45. Creticos PS, et al. Initial immunotherapy trial to explore the safety, tolerability and immunogenicity of subcutaneous injections of an AMB a 1 immunostimulatory oligonucleotide conjugate (AIC) in ragweed allergic adults. J Allergy Clin Immunol 2001;107:S216.
46. Creticos PS, et al. Immunostimulatory oligodeoxynucleotides conjuated to Amb a 1: safety, skin test reactivity, and basophil histamine release. J Allergy Clin Immunol 2000;105:S70 [abstract].
47. Tulic MK, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235-241.